While investigating the prognostic potential of cMo IFN in cancer patients, we observed significant overexpression of TMEM176A and TMEM176B genes in cMo IFN from responders, though both genes were differentially expressed even before treatment (Figure S5A). Here, TMEM176A is linked to cancer.